How's my detailing? Dial 1-877-RX-DDMAC

Share this article:
How's my detailing? Dial 1-877-RX-DDMAC
How's my detailing? Dial 1-877-RX-DDMAC
The FDA is asking healthcare professionals to keep an eye out for violative promotion and to call 1-877-RX-DDMAC or emailing badad@fda.com when they see it.

"Recognize and report" is the message of the agency's Bad Ad Program, an educational outreach effort by the Division of Drug Marketing, Advertising and Communications (DDMAC) that will “help healthcare providers recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency,” according to DDMAC director Tom Abrams.

The program will be rolled out in three phases, said FDA. In Phase 1, DDMAC will engage healthcare providers and distribute educational materials at select medical conventions and through partnerships with medical societies. Phases 2 and 3 “will expand the FDA's collaborative efforts and update the educational materials developed for Phase 1,” said FDA.

The program represents an effort to expand the agency's monitoring capability by enlisting the targets of promotion to serve as FDA's eyes and ears on the street. Traditionally, the agency noted, monitoring efforts have relied on reviews of promotional pieces submitted by drug companies, industry complaints and field surveillance at big medical conventions.

“Although these efforts are effective, the agency has limited ability to monitor promotional activities that occur in private,” said FDA.

Reports can be submitted anonymously, though the agency will encourage callers to leave contact info for follow-ups, the agency said. The website for the program is at: www.fda.gov/badad.
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.